{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Toxo IgG II",
        "LIAISON\u00ae Control Toxo IgG II"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K132234",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981498",
        "K122397"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD",
        "JJX"
    ],
    "Summary Letter Date": "July 11, 2013",
    "Summary Letter Received Date": "July 18, 2013",
    "Submission Date": "July 17, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.3780",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii, Serological Reagent",
        "Single (Specified) analyte controls (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Toxoplasma gondii"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect immunoassay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Toxo IgG II assay and quality control for detection of IgG antibodies to Toxoplasma gondii using chemiluminescent immunoassay.",
    "Indications for Use Summary": "Qualitative determination of specific IgG antibodies to Toxoplasma gondii in human serum to aid in the assessment of patient serological status and immune status including pregnant women; controls monitor assay performance on the LIAISON XL Analyzer.",
    "fda_folder": "Microbiology"
}